ArticlePediatric nephrology (Berlin, Germany)2026
Risk stratification guided treatment and outcomes of pediatric membranous nephropathy.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric membranous nephropathy (MN) is a rare glomerular disease with limited data available. This single-center study aims to describe risk stratification-based treatment and its outcomes.
methodsThis retrospective observational study included children younger than 18 years of age with primary MN diagnosed from July, 2021 to December, 2024. KDIGO risk stratification criteria were modified with author consensus for pediatric thresholds, and children were stratified into low, moderate, high and very high risk. Immunosuppressive drugs included calcineurin inhibitors (CNIs), cyclophosphamide (CYC) and rituximab (RTX). Outcomes included complete remission, partial remission, no response, relapse, and decline in kidney function at 12 months and last follow-up, and were summarized across baseline risk categories and initial treatment groups. Time to first complete or partial remission was assessed using Kaplan-Meier analysis and compared using the log-rank test.
resultsThirty-three children were included with a mean age of 11.15 ± 3.16 years, of whom 24 (73%) were males. Baseline risk stratification showed 24 (73%) were in the high-risk category. Initially, CNIs were administered in 17 (51.5%), while CYC and RTX in 5 (15%) and 3 (9%) patients, respectively. Among high-risk patients, non-response was observed in 8 (34%) at 12 months and 4 (17%) at last follow-up. Anti-PLA2R positivity was associated with better outcomes, with higher rates of complete or partial remission (p = 0.03). At last follow-up, 4 (12.1%) children demonstrated decline in kidney function.
conclusionWe describe treatment allocation and short-term outcomes in pediatric MN using a modified risk stratification-based approach. Higher risk categories appeared to have less favorable responses, while anti-PLA2R positivity was associated with better outcomes.
Indexed as
Identifiers
42340439What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.